Raritan: Johnson & Johnson has received priority review from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine ...

Johnson & Johnson (NYSE: JNJ) ranks among the best forever stocks to invest in. Prior to the company’s second-quarter ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded ...

Johnson & Johnson revised its fiscal year 2025 guidance. The company expects adjusted earnings of $10.80-$10.90, up from ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Producer prices stay flat in June, easing inflation fears. Strong J&J earnings boost pharma stocks while ASML and energy shares drag markets.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

In the second quarter, Johnson & Johnson JNJ saw 4.6% constant currency sales growth and a 1.8% decline in adjusted diluted ...